YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Drug Evaluation of Ursodeoxycholic Acid Use for Treatment of Cholestasis Associated with TPN Therapy in Neonate

신생아의 TPN 요법 시 발생되는 Cholestasis 치료를 위한 Ursodeoxycholic Acid의 약물사용 평가

  • Received : 2010.03.25
  • Accepted : 2010.06.10
  • Published : 2010.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Total parenteral nutrition (TPN) is necessary to neonates in neonatal intensive care unit (NICU) for survival and growth because of impossible of enteral feeding. Long-term TPN can be associated with a broad spectrum of hepatobiliary disorder, ranging from mild hepatic dysfunction to severe end-stage liver disease. Cholestasis developed most commonly in neonate, ursodeoxycholic acid (UDCA) is widely used in adult with cholestatic and non-cholestatic liver diseases but there have been limited data on the effects in neonate with PNAC. This study was performed retrospectively to review all medical histories of the total 30 neonates with was administrated UDCA for treatment to parenteral nutrition associated cholestasis (PNAC) at Chungbuk National University Hospital NICU from April 2002 to December 2008. UDCA was administrated at bilirubin is over 2 mg/dl. The criterias for drug evaluation were included hepatic biochemical marker such as direct bilirubin, total bilirubin, AST, ALT, ALP and GGT, TPN therapy period, cholestasis development period, UDCA treatment period, UDCA dosage and adverse effect. In the results, Post-UDCA treatment significant was decreased direct bilirubin, total bilirubin, AST and ALP (p<0.05), and was decreased GGT (p>0.05) and slightly was increased ALT (p>0.05). Reffective timect biDCA was appear at mean $10.5{\pm}1.3$ days, iDCA administration period was mean $64.4{\pm}5.9$ days, cholestasis period was mean $71.9{\pm}6.4$ days and UDCA dosage was mean $22.9{\pm}0.9$ mg/kg/day. Common adverse effects is diarrhea, 5 patients arised mild diarrhea but it possible also related with increased enteral feeding. In conclusion, iDCA can decrease direct bilirubin that major parameter t bcholestasis and oher hepatic biochemical makers. UDCA is effective on PNAC without any serious side effect and cost-effective. Although no greatly shortening cholestasis period, but can protect to develop into severe liver disease and other complication or death. Based on these result, UDCA is recommended for treatment of cholestasis at direct bilirubin is over 2 mg/dl.

Keywords

References

  1. Koda-Kimble, M. A., Young, L. Y., Kradjan, W. A., Guglielmo, B. J., Alldredge, B. K. and Corelli, R. L. : Applied Therapeutics. Lippincott Williams & Wilkins 8 (2005)
  2. Kelly, D. A. : Liver complication of pediatric parenteral nutrition - Epidemiology. Nutrition. 14, 153 (1998). https://doi.org/10.1016/S0899-9007(97)00232-3
  3. Deckers-Kocken, J. M., Peter G. J. Nikkels, André Verheem, Roderick H. J. Houwen, and Louis M. A. Akkermans : Atypical findings in a rat model for parenteral nutrition-induced cholestasis. Nutrition Research 26, 664 (2006). https://doi.org/10.1016/j.nutres.2006.09.025
  4. McKiernan, P. J. : Neonatal cholestasis. Semin Neonatol 7, 153 (2002). https://doi.org/10.1053/siny.2002.0103
  5. Chen, C. Y., Tsao, P. N., Chen, H. L., Chou, H. C., Hsieh, W. S. and Chang, M. H. : Ursodeoxycholic acid (UDCA) therapy in very low birth weight infants with parenteral nutrition associated cholestasis. The Journal of Pediatrics. 317 (2004).
  6. Kaufman, S. S. : Prevention of parenteral nutrition-associated liver disease in children. Pediatric Transplantation 6, 37 (2002). https://doi.org/10.1034/j.1399-3046.2002.1o061.x
  7. Yang, R. R. : The effect of glutamine on cholestasis caused by total parenteral nutrition. Zhonghua Wai Ke Za Zhi Chinese Journal of Surgery] 31, 94 (1993).
  8. Gura, K. M., Lee, S., Valim, C., Zhou, J., Kim, S., Modi, B. P., Arsenault, D. A., Strijbosch, R. A., Lopes, S., Duggn, C. and Puder, M. : Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics, Mar. 121, e678 (2008). https://doi.org/10.1542/peds.2007-2248
  9. Takehara, H., Hono, M., Kameoka, K. and Komi, N. : A new method of total nutrition for surgical neonate: It is possible that cyclic TPN prevents intrahepatic cholestasis. The Tokushima Journal of Experimental Medicine. 37, 97 (1990).
  10. Spagnuolo, M. I., Iorio, R., Vegnente, A. and Guarino, A. : Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: A pilot study. Gastroenterology 111, 716 (1996). https://doi.org/10.1053/gast.1996.v111.pm8780577
  11. Al-Hathlol, K., Al-Madani, A., Al-saif, S., Abulaimoun, B., Al- Tawil, K. and El-Demerdash, A. : Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Medical Journal 47, 147 (2006).
  12. Hutchins, G. F. and Gollan, J. L. : Recent developments in the pathophysiology of cholestasis. Clinics in Liver Disease. 8, 1. (2004). https://doi.org/10.1016/S1089-3261(03)00125-9
  13. Trauner, M. and Graziaderi, I. W. : Review article : Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Alimentary Pharmacology & Therapeutics 13, 979 (1999). https://doi.org/10.1046/j.1365-2036.1999.00596.x
  14. Taketomo, C. K., Hodding, J. H. and Kraus, D. M. : Pediatric dosage handbook. Lexi-comp. 16th edition (2009).
  15. Lee, M. : Basic skills interpreting laboratory data. American Society of Health-System Phamacist. Bethesda, Maryland. 3th Edition (2004).
  16. Oshita, M., Takehara, H., Yamaguchi, M., Doi, K., Ueda, N., Naito, S., Hiraoka, I. and Tashiro, S. : Significance of administration of fat emulsion : Hepatic change in infant rats receiving total parenteral nutrition with and without fat. Clinical Nutrition. 23, 1060 (2004). https://doi.org/10.1016/j.clnu.2004.01.009